Cite
HARVARD Citation
Kappos, L. et al. (2018). 061 Ocrelizumab reduces disability progression independent of relapse activity in patients with relapsing multiple sclerosis (RMS) (ENCORE). Journal of neurology, neurosurgery and psychiatry. 89 (6), p. A25. [Online].